SCHEDULE: Deep Track Capital Discloses 9.99% Stake in ProMIS Neurosciences

Deep Track Capital and its affiliates have reported a 9.99% beneficial ownership stake in ProMIS Neurosciences Inc., including common shares and exercisable warrants.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., David Kroin, and Deep Track Special Opportunities Fund, LP have filed a Schedule 13G disclosing beneficial ownership in ProMIS Neurosciences Inc.
• Deep Track Capital, LP and David Kroin collectively beneficially own 902,561 common shares, representing 9.99% of the class.
• Deep Track Biotechnology Master Fund, Ltd. beneficially owns 703,457 common shares, representing 7.79% of the class.
• Deep Track Special Opportunities Fund, LP beneficially owns 199,104 common shares, representing 2.20% of the class.
• The aggregate beneficial ownership includes 835,655 warrants exercisable into common stock, subject to a 9.99% maximum exercise limitation.
• The ownership calculation is based on 9,034,646 total common shares outstanding, derived from a November 12, 2025 10-Q, a January 30, 2026 8-K, and convertible common stock by the reporting person.
• The securities were not acquired for the purpose of changing or influencing the control of ProMIS Neurosciences Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a specialized institutional investor like Deep Track Capital can be interpreted as a strong vote of confidence in ProMIS Neurosciences Inc.'s potential, even though the filing itself is purely a disclosure.

Positives

• A significant institutional investor, Deep Track Capital, has taken a substantial stake (9.99%) in ProMIS Neurosciences Inc., which can be viewed as a vote of confidence in the company's future prospects.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

StockSavvy.ai notes that a significant stake by a specialized biotechnology investment firm like Deep Track Capital in ProMIS Neurosciences Inc. could signal increased institutional interest in the neuroscience sector, particularly in companies developing treatments for neurological disorders. This type of disclosure often attracts attention from other investors looking for validation in emerging or high-growth areas within biotech.

Comparison to Industry Standards

• Deep Track Capital's 9.99% stake in ProMIS Neurosciences Inc. is a substantial position, nearing the 10% threshold that often triggers more stringent reporting requirements and can be seen as a strong conviction play.
• For a biotechnology company, attracting a dedicated biotech fund like Deep Track Capital, known for its focus on life sciences, is generally a positive indicator, suggesting a belief in the company's pipeline or technology.
• While direct comparisons to specific projects or results are not available in this filing, the investment itself aligns with a trend of specialized funds taking concentrated positions in promising, often smaller, biotech firms.

Stakeholder Impact

• Shareholders: Existing shareholders may view this as a positive signal, potentially leading to increased investor confidence and interest in the stock.
• Potential Investors: The disclosure of a significant institutional stake could attract new investors who follow the investment strategies of firms like Deep Track Capital.

Key Dates

Keywords

ProMIS Neurosciences Inc., Deep Track Capital, Schedule 13G, Beneficial Ownership, Common Shares, Biotechnology, Neurosciences, Institutional Investor, Warrants, Equity Stake